首页> 外文OA文献 >Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives

【2h】

Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives

机译：巴西私人和公共卫生保健系统视野中达比加群与华法林对非瓣膜性心房颤动患者的成本效果和成本效用分析以及中风和系统性栓塞的危险因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Pepe Ribeiro de Souza Camila; Bolzachini Santoni Natália; Gomes de Melo Thais; Jansen de Oliveira Figueiredo Marcio; da Costa Darrieux Francisco Carlos; Soares Piegas Leopoldo; Ouriques Martins Sheila;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
2. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
3. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population [J] . Amin Alpesh, Keshishian Allison, Trocio Jeffrey, Current medical research and opinion . 2017,第9期

机译：与美国医疗保险人口的华法林相比，中风/全身栓塞患者的中风/全身栓塞患者的严重出血和相关成本
4. Prediction of Stroke Risk Factors for Better Pre-emptive Healthcare: A Public-Survey-Based Approach [C] . Debayan Banerjee, Jagannath Singh International Conference on Advanced Computing and Intelligent Engineering . 2021

机译：预测更好的先发制前医疗保健的行程风险因素：基于公开的方法
5. Dabigatran versus warfarin for the prevention of stroke in patients with chronic nonvalvular atrial fibrillation. [D] . Qiu, Fen. 2011

机译：达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
6. The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis [O] . Oh Young Bang, Young Keun On, Myung-Yong Lee, 2020

机译：亚洲患者中风/全身栓塞和主要出血的风险与非维生素K口服抗凝血治疗的非瓣膜心房颤动与华法林相比：现实世界数据分析的结果
7. Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts” [O] . Jonathan P. Piccini, Susanna R. Stevens, YuChiao Chang, 2013

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives

著录项

引文网络

相似文献

相关主题

期刊订阅